Issue: March 2017, Posted Date: 3/23/2017

Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time

 
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the US prescription market for the first time with Allergan’s RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05%.

 

This approval and launch makes the Aptar Pharma Ophthalmic Squeeze Dispenser the very first, and only, US FDA-approved multidose delivery system to handle prescription eye treatment formulations without any preservatives.

Photo Courtesy of Allergan


Aptar Pharma is working closely with eye care specialist Allergan to improve patient safety, achieve dosing accuracy, and maintain product integrity. Dry
eye patients use eye drops on a regular basis, and often for the rest of their lives. It is well-proven that preserved medications may cause unpleasant and sometimes serious side effects.

 

The increasing number of patients experiencing eye irritation or allergic reactions with preserved formulations appreciate the fact that preservatives can be removed from eye care medications with Aptar Pharma’s Ophthalmic Squeeze Dispenser system. RESTASIS and RESTASIS MULTIDOSE are FDA-approved prescription treatments to help patients suffering from Chronic Dry Eye to make more of their own tears.

 

Aptar Pharma’s Ophthalmic Squeeze Dispenser system is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions. Patients and consumers in Europe, Latin America, and Asia have benefited from this technology since 2012 with more than 100 commercial references now available on the market. RESTASIS is not an artificial tear. It is a prescription medicine that helps increase the eyes' natural ability to produce tears.

 

“Our Ophthalmic Squeeze Dispenser technology has been a great success for our customers,” explained Salim Haffar, President, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the FDA.”

 

Mr. Haffar also points out the user-friendliness of the system, “The ergonomic and pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers around the world.”

 

 

Aptar Pharma's Ophthalmic Squeeze Dispenser provides a unique competitive advantage by addressing the global trend toward patient-friendly, cost-effective, and preservative-free multidose dispensers.

 

Aptar Pharma is part of AptarGroup, Inc., a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, IL, with manufacturing facilities in North America, Europe, Asia, and South America. For more information, visit aptar.com/pharma.


Related Taxonomy
Popularity:
This record has been viewed 409 times.



















- SHL


Click here to see the showcases


RDD (Respiratory Drug Delivery)
April 25-28
Nice, France

Pre-filled Syringes East Coast
April 26-27
Boston, MA


AAPS National Biotechnology Meeting
May 1-3
San Diego, CA

Innovation Networking Summit & Table-top Exhibition
May 4-5
Hilton Hotel, Parsippany, NJ

CPhI North America & Informex
May 16-18
2017 Philadelphia, PA

Pre-filled Syringes West Coast
June 5th & 6th, San Diego, USA

BIO 2017

June 19 - 22
San Diego, CA

Controlled Release Society Meeting
July 16-19 Boston, MA

CPhI Worldwide
October 24-26
Frankfurt, Germany

Universe of Prefilled Syringes & Injection Devices Europe
November 7-8
Nienna, Austria

AAPS
November 12-17
San Diego, CA

 



Copyright © 2017  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions